Advanced search
Publication Cover
Current Medical Research and Opinion Volume 32, 2016 - Issue 11
Submit an article Journal homepage
534
Views
11
CrossRef citations to date
0
Altmetric
Neurology

Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States

Aseel Bin SawadInternational Center for Pharmaceutical Economics and Policy, MCPHS University, Boston, MA, USA; ;Department of Clinical Pharmacy, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia; Correspondence[email protected] [email protected]
,
Enrique Seoane-VazquezInternational Center for Pharmaceutical Economics and Policy, MCPHS University, Boston, MA, USA;
,
Rosa Rodriguez-MonguioDepartment of Health Policy and Management, University of Massachusetts Amherst, Amherst, MA, USA;
&
Fatema TurkistaniInternational Center for Pharmaceutical Economics and Policy, MCPHS University, Boston, MA, USA; ;Department of Clinical Pharmacy, Taibah University, Medina, Kingdom of Saudi Arabia
Pages 1783-1788 | Received 02 Apr 2016, Accepted 27 Jun 2016, Published online: 02 Aug 2016

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Emanuele D’Amico, Clara G Chisari, Lara Gitto, Aurora Zanghì, Simona Toscano & Francesco Patti. (2019) Pharmacoeconomics of synthetic therapies for multiple sclerosis. Expert Opinion on Pharmacotherapy 20:11, pages 1331-1340.
Read now

Articles from other publishers (10)

Hana Althobaiti, Enrique Seoane-Vazquez, Lawrence M. Brown, Marc L. Fleming & Rosa Rodriguez-Monguio. (2023) Disentangling the Cost of Orphan Drugs Marketed in the United States. Healthcare 11:4, pages 558.
Crossref
Joseph R. Berger, Thomas P. Leist, Benjamin M. Greenberg & Kottil Rammohan. (2021) Physician Compensation in the United States – Through the Lens of the MS Neurologist. Multiple Sclerosis and Related Disorders 50, pages 102847.
Crossref
Fatema Turkistani & Aseel Bin Sawad. (2020) Pharmaceutical pricing benchmarks: governmental versus private sector. Journal of Comparative Effectiveness Research 9:15, pages 1091-1100.
Crossref
Aseel Bin Sawad & Fatema Turkistani. (2020) Treatment of venous leg ulcers using bilayered living cellular construct. Journal of Comparative Effectiveness Research 9:13, pages 907-918.
Crossref
Izumi Kawachi, Shuichi Okamoto, Mariko Sakamoto, Hiroyuki Ohta, Yusuke Nakamura, Kosuke Iwasaki, Manami Yoshida, Shinzo Hiroi & Mieko Ogino. (2019) Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database. BMC Neurology 19:1.
Crossref
Youngran Kim, Trudy Millard Krause, Philip Blum & Léorah Freeman. (2019) Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis. Multiple Sclerosis and Related Disorders 30, pages 69-75.
Crossref
Sarah L Minden, R Philip Kinkel, Helene T Machado, Jonathan S Levin, Meredith B Rosenthal & Lisa I Iezzoni. (2019) Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?. Multiple Sclerosis Journal - Experimental, Translational and Clinical 5:1, pages 205521731882088.
Crossref
Daniel M. Hartung. (2017) Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA. Neurotherapeutics 14:4, pages 1018-1026.
Crossref
Erin P. Ferranti, Ruth Grossmann, Angela Starkweather & Margaret Heitkemper. (2017) Biological determinants of health: Genes, microbes, and metabolism exemplars of nursing science. Nursing Outlook 65:5, pages 506-514.
Crossref
Aseel Bin Sawad, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio & Fatema Turkistani. (2017) Cost–effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis. Journal of Comparative Effectiveness Research 6:2, pages 97-108.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.